Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome

Table 3 Univariate analysis of the variables affecting hematological TRM, CIR, DFS and OS in patients with MLL-PTD after allo-HSCT

Variables	Number (n,%)	P value
Variables	Number (n,%)	TRM	CIR	DFS	OS
Age of recipient		0.965	0.291	0.410	0.442
<50 years	31(64.6%)
≥ 50 years	17(35.4%)
Underlying disease		0.675	0.115	0.151	0.157
AML	33(68.8%)
MDS-EB1/2	15(31.2%)
ABO compatibility		0.264	0.009	0.38	0.484
Compatible	24(50.0%)
Incompatible	24(50.0%)
Donor type		0.271	0.653	0.544	0.560
HLA-matched sibling	12(25.0%)
Haploidentical	36(75.0%)
Prophylactic DLI	2(4.2%)	0.325	0.591	0.735	0.702
FLT3-ITD positive	10(20.8%)	0.067	0.868	0.068	0.041
Pre-transplantation FCM		0.056	0.504	0.291	0.232
Negative	23(47.9%)
Positive	25(52.1%)
Pre-transplantation WT1		0.339	0.166	0.843	0.854
WT1 < 0.6%	19(40.4%)
WT1 ≥ 0.6%	28(59.6%)
Pre-transplantation MLL-PTD		0.105	0.967	0.202	0.202
MLL-PTD/ABL ≥ 1.0%	25(52.1%)
MLL-PTD/ABL<1.0%	23(47.9%)
Post-transplantation MLL-PTD		0.277	< 0.001	< 0.001	< 0.001
MLL-PTD/ABL ≥ 1.0%	8(16.7%)
MLL-PTD/ABL<1.0%	38(79.2%)

TRM treatment-associated mortality, CIR cumulative incidence of relapse, DFS disease-free survival, OS overall survival, HLA human leukocyte antigen, allo-HSCT allogeneic hematopoietic stem cell transplantation, DLI donor lymphocyte infusion, MLL-PTD mixed lineage leukemia-partial tandem duplication, AML acute myeloid leukemia, MDS myelodysplastic syndrome

ISSN: 1471-2407